Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Instagram
  • Listen to CMAJ podcasts
Practice
Open Access

Management of γ-hydroxybutyrate intoxication and withdrawal

Victoria K. Weaver, Sarah Ickowicz and Nadia Fairbairn
CMAJ June 05, 2023 195 (22) E786; DOI: https://doi.org/10.1503/cmaj.221564
Victoria K. Weaver
British Columbia Centre on Substance Use (Weaver, Fairbairn); Department of Medicine (Weaver, Ickowicz, Fairbairn), University of British Columbia, Vancouver, BC
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sarah Ickowicz
British Columbia Centre on Substance Use (Weaver, Fairbairn); Department of Medicine (Weaver, Ickowicz, Fairbairn), University of British Columbia, Vancouver, BC
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nadia Fairbairn
British Columbia Centre on Substance Use (Weaver, Fairbairn); Department of Medicine (Weaver, Ickowicz, Fairbairn), University of British Columbia, Vancouver, BC
MD MHSc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading

γ-Hydroxybutyrate (GHB) induces euphoria and relaxation

Also known as liquid ecstasy or “G,” GHB and its analogues (e.g., γ-butyrolactone) are GHB- and γ-aminobutyric acid-B (GABAB) receptor agonists within the central nervous system.1–3 Synthetic GHB is a tasteless, colourless liquid used for purported anabolic effects,1,2 increasing relaxation and euphoria, enhancing sexual experiences or as an agent in drug-facilitated sexual assaults.1 It is detectable in urine for 5–12 hours after ingestion, but is not included on standard toxicology screens.2,3 Confirmatory testing with gas chromatography–mass spectrometry requires consultation with provincial toxicology laboratories.2

Tolerance can develop within several days of continuous use1,3,4

Doses of GHB range from 500 mg to 5 g, often taken in “capfuls.”2,4 Given a serum half-life of 20–30 minutes,2 people who have developed a tolerance may require doses every 30 minutes to prevent withdrawal symptoms.2,5

Poisoning can develop rapidly

Toxicity is dependent on dose — doses of 20–30 mg/kg may be stimulating, while doses of 40–60 mg/kg can lead to myoclonus, respiratory depression, bradycardia and coma.3 Acute intoxication generally resolves in 6–8 hours with supportive management and airway stabilization.2,5

Withdrawal from GHB may be fatal if unrecognized

Withdrawal can manifest within 1–6 hours following cessation.2–4 Initial symptoms include diaphoresis, tachycardia and anxiety, and may rapidly progress to hallucinations, delirium, seizures or death if not appropriately managed.1,2,4 Withdrawal can persist up to 15 days despite treatment.2,4

Benzodiazepines are first-line therapy for GHB withdrawal

Specific choice of benzodiazepine depends on patient factors, including comorbidities, age and hepatic function. Diazepam doses of up to 300 mg/d have been used.4 Adjuncts targeting the GABAB receptor, such as baclofen, initially dosed at 10 mg 3 times daily, may potentiate the effects of benzodiazepines.1,2 Benzodiazepine resistance has been reported.1,5 Clinicians should consider transitioning to phenobarbital and monitoring in a high-acuity unit if withdrawal symptoms worsen despite escalating benzodiazepine doses.1,4,5

Footnotes

  • Competing interests: None declared.

  • This article has been peer reviewed.

  • Funding: This work was supported by the National Institute on Drug Abuse (R25-DA037756 to Victoria Weaver). Nadia Fairbairn is supported by a Philip Owen Professorship in Addiction Medicine at the University of British Columbia, and a Scholar Award from the Michael Smith Foundation for Health Research– St. Paul’s Hospital Foundation.

This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0) licence, which permits use, distribution and reproduction in any medium, provided that the original publication is properly cited, the use is noncommercial (i.e., research or educational use), and no modifications or adaptations are made. See: https://creativecommons.org/licenses/by-nc-nd/4.0/

References

  1. ↵
    1. Tay E,
    2. Lo WKW,
    3. Murnion B
    . Current insights on the impact of gamma-hydroxybutyrate (GHB) abuse. Subst Abuse Rehabil 2022;13:13–23.
    OpenUrl
  2. ↵
    1. Snead OC III.,
    2. Gibson KM
    . Gamma-hydroxybutyric acid. N Engl J Med 2005;352:2721–32.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Haroz R,
    2. Farmer BM
    . γ-hydroxybutyric acid (γ-hydroxybutyrate). In: Nelson LS, Howland MA, Lewin NA, et al., editors. Goldfrank’s Toxicologic Emergencies, 11e. New York: McGraw-Hill Education; 2019.
  4. ↵
    1. Kamal RM,
    2. van Noorden MS,
    3. Wannet W,
    4. et al
    . Pharmacological treatment in γ-hydroxybutyrate (GHB) and γ-butyrolactone (GBL) dependence: detoxification and relapse prevention. CNS Drugs 2017;31:51–64.
    OpenUrl
  5. ↵
    1. Freeman G,
    2. Siefried KJ,
    3. Roberts DM,
    4. et al
    . Phenobarbital to manage severe gamma-hydroxybutyrate withdrawal: a case series. Drug Alcohol Rev 2023;42:27–32.
    OpenUrl
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 195 (22)
CMAJ
Vol. 195, Issue 22
5 Jun 2023
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Management of γ-hydroxybutyrate intoxication and withdrawal
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Management of γ-hydroxybutyrate intoxication and withdrawal
Victoria K. Weaver, Sarah Ickowicz, Nadia Fairbairn
CMAJ Jun 2023, 195 (22) E786; DOI: 10.1503/cmaj.221564

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Management of γ-hydroxybutyrate intoxication and withdrawal
Victoria K. Weaver, Sarah Ickowicz, Nadia Fairbairn
CMAJ Jun 2023, 195 (22) E786; DOI: 10.1503/cmaj.221564
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • γ-Hydroxybutyrate (GHB) induces euphoria and relaxation
    • Tolerance can develop within several days of continuous use1,3,4
    • Poisoning can develop rapidly
    • Withdrawal from GHB may be fatal if unrecognized
    • Benzodiazepines are first-line therapy for GHB withdrawal
    • Footnotes
    • References
  • Responses
  • Metrics
  • PDF

Related Articles

  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • SARS-CoV-2 vaccination in pregnancy
  • Infantile perianal pyramidal protrusion
  • Topical nonsteroidal anti-inflammatory drugs
Show more Practice

Similar Articles

Collections

  • Article Types
    • Five Things to Know About
  • Topics
    • Addiction medicine
    • Emergency medicine
    • Internal medicine

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: [email protected]

CMA Civility, Accessibility, Privacy

 

Powered by HighWire